1.Pancreatic Metastasis in a Child Suffering with Treated Stage 4 Neuroblastoma.
Eun Young KIM ; So Young YOO ; Ji Hye KIM ; Ki Woong SUNG
Korean Journal of Radiology 2008;9(1):84-86
We present here a very rare case of metastatic relapse in the pancreas of a 4-year-old boy who had been treated for stage 4 neuroblastoma. Computed tomography showed multiple metastatic masses in the pancreas with secondary pancreatitis. To the best of our knowledge, this is the first case report of pancreatic metastasis in a child with neuroblastoma.
Adrenal Gland Neoplasms/diagnosis/*pathology
;
Child, Preschool
;
Contrast Media
;
Diagnosis, Differential
;
Diagnostic Imaging
;
Humans
;
Male
;
Neuroblastoma/diagnosis/*secondary
;
Pancreatic Neoplasms/diagnosis/*secondary
2.Laboratory Evaluation of Bone Marrow Metastasis: Single Institute Study.
Hyeong Kee YUN ; Myung Geun SHIN ; Ding BO ; Da Woon KIM ; Duck CHO ; Jong Hee SHIN ; Soon Pal SUH ; Dong Wook RYANG
The Korean Journal of Laboratory Medicine 2007;27(2):96-101
BACKGROUND: The incidence of bone marrow (BM) metastasis might be related with the occurrence of malignant tumors in ethnic groups. So, we investigated the type and the frequency of metastatic tumors of BM and analyzed the clinicopathologic variables of BM metastasis. METHODS: This study included 932 cases of primary malignant tumor which were requested for BM study from January 1995 to June 2006 in Chonnam National University Hospital and Chonnam National University Hwasun Hospital. Peripheral blood smears (PBS); aspirates, touch prints, and trephine biopsies of BM; and medical records including other laboratory test results were reviewed. RESULTS: Overall frequency of BM metastasis was 11.9% (111/932). Primary tumors with BM involvement in children comprised neuroblastoma (74.1%), rhabdomyosarcoma (7.4%), and malignant lymphoma (7.4%). For adult patients, they consisted of malignant lymphoma (56.0%), gastrointestinal cancer (20.2%), and lung cancer (6.0%). In the case of malignant lymphoma, diffuse large cell lymphoma was the most frequent one. Laboratory findings of patients with BM metastasis commonly showed anemia and thrombocytopenia; in addition, serum LD, ALP, AST and ALT were elevated in 81.5% (75/92), 63.4% (59/93), 63.5% (61/96) and 33.3% (32/96), respectively. Leukoerythroblastosis was observed only in 19.8% (22/111) on PBS examination. CONCLUSIONS: The most common non-hematopoietic metastatic tumor was neuroblastoma in children and gastrointestinal tumors in adults. Leukoerythroblastosis, anemia, and the elevation of serum LD, ALP, and AST were useful markers for the prediction of BM metastasis.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Bone Marrow Examination
;
Bone Marrow Neoplasms/diagnosis/pathology/*secondary
;
Child
;
Child, Preschool
;
Female
;
Gastrointestinal Neoplasms/pathology
;
Hematologic Tests
;
Humans
;
Infant
;
Male
;
Middle Aged
;
Neuroblastoma/pathology
3.Assessment of Serologic Immunity to Diphtheria-Tetanus-Pertussis After Treatment of Korean Pediatric Hematology and Oncology Patients.
Hyo Jin KWON ; Jae Wook LEE ; Nak Gyun CHUNG ; Bin CHO ; Hack Ki KIM ; Jin Han KANG
Journal of Korean Medical Science 2012;27(1):78-83
The aim of this study was to investigate the diphtheria-tetanus-pertussis antibody titers after antineoplastic treatment and to suggest an appropriate vaccination approach for pediatric hemato-oncologic patients. A total of 146 children with either malignancy in remission after cessation of therapy or bone marrow failure were recruited. All children had received routine immunization including diphtheria-tetanus-acellular pertussis vaccination before diagnosis of cancer. The serologic immunity to diphtheria, tetanus and pertussis was classified as: completely protective, partially protective, or non-protective. Non-protective serum antibody titer for diphtheria, tetanus and pertussis was detected in 6.2%, 11.6%, and 62.3% of patients, respectively, and partial protective serum antibody titer for diphtheria, tetanus and pertussis was seen in 37%, 28.1%, and 8.9% of patients. There was no significant correlation between the severity of immune defect and age, gender or underlying disease. Revaccination after antineoplastic therapy showed significantly higher levels of antibody for each vaccine antigen. Our data indicates that a large proportion of children lacked protective serum concentrations of antibodies against diphtheria, tetanus, and pertussis. This suggests that reimmunization of these patients is necessary after completion of antineoplastic treatment. Also, prospective studies should be undertaken with the aim of devising a common strategy of revaccination.
Adolescent
;
Age Factors
;
Antibodies, Bacterial/blood/immunology
;
Antineoplastic Agents/therapeutic use
;
Child
;
Child, Preschool
;
Diphtheria/immunology/prevention & control
;
Diphtheria-Tetanus-acellular Pertussis Vaccines/*immunology
;
Female
;
Hematologic Neoplasms/*diagnosis/drug therapy
;
Humans
;
Immunization, Secondary
;
Lymphoma/diagnosis/drug therapy
;
Male
;
Neuroblastoma/diagnosis/drug therapy
;
Sex Factors
;
Tetanus/immunology/prevention & control
;
Whooping Cough/immunology/prevention & control
4.Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis.
Sang Hyuk PARK ; Sollip KIM ; Chan Jeoung PARK ; Seongsoo JANG ; Hyun Sook CHI ; Kyung Nam KOH ; Ho Joon IM ; Jong Jin SEO
Annals of Laboratory Medicine 2013;33(2):89-96
BACKGROUND: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy. METHODS: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy. RESULTS: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P=0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P=0.852). CONCLUSIONS: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Bone Marrow/*pathology
;
Bone Marrow Cells/*cytology
;
Bone Marrow Neoplasms/*diagnosis/secondary
;
Cell Differentiation
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Infant
;
Karyotyping
;
Male
;
Neoplasm Grading
;
Neuroblastoma/*diagnosis/drug therapy/pathology
;
Prognosis
;
Survival Analysis
;
Young Adult